Casein hydrolysate 

Casein hydrolysate is an orally effective, multi-functional mixture of bioactive peptides, a hydrolysis product of casein (HY-125865), containing ACE inhibitors and immunomodulatory target regulators, among others. Casein hydrolysate releases short-chain bioactive peptides through enzymatic hydrolysis of casein, increasing cellular glutathione and catalase levels, enhancing ConA-induced IL-2 production, and exhibiting metal ion chelation, free radical scavenging, antibacterial, and mineral absorption-promoting effects. Casein hydrolysate lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE) and reducing bradykinin degradation^[1][2][3].

Casein hydrolysate inhibits lipid peroxidation at concentrations of 0.05-0.5 mg/mL, and can chelate Fe²⁺, scavenging peroxyl radicals and hydroxyl radicals^[1].
The IC50 value of casein hydrolysate (0-50% (v/v); 24 h) on Jurkat T cells ranges from 19.5%-66.8% (v/v), and does not affect cell membrane integrity at concentrations ≤1% (v/v)^[2].
Casein hydrolysate (0.05% (v/v); 24 h) significantly increased GSH content in Jurkat cells in antioxidant experiments, but did not affect superoxide dismutase (SOD) activity^[2].
Casein hydrolysate (0.05% (v/v); 24 h) neither produced genotoxicity nor protected cells from H₂O₂-induced DNA damage in Caco-2 cell comet assays^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Casein hydrolysate-derived peptides Ile-Pro-Pro/Val-Pro-Pro (≤5 mg/kg; orally gavage; single dose; 6-8 hours after administration) significantly reduces systolic blood pressure in spontaneously hypertensive rats (SHR), while a 10 mg/kg dose had no effect on the systolic blood pressure of normal rats^[1].
Casein hydrolysate-derived peptide Leu-Lys-Pro-Asp-Meth (100 μg/kg; i.v.; single dose; immediately after administration) reduces blood pressure by 30 mmHg in spontaneously hypertensive rats (SHR), and its hydrolysis product Leu-Lys-Pro (30 μg/kg; intravenous injection; single dose; immediately after administration) reduces blood pressure by 50 mmHg^[1].
Casein phosphopeptides (CPP) from casein hydrolysate inhibits bone resorption, stimulates bone mineralization, and promotes calcium integration into bone tissue in a decalcified bone matrix rat model^[1].
Casein hydrolysate-related immunomodulatory peptide-derived IgY prevents bacterial adhesion to the intestinal epithelium and dose-dependently prevents enterotoxigenic E. coli infection in a colostrum-deficient piglet model of enterotoxigenic E. coli infection^[1].
Casein hydrolysate stimulates the production of superoxide anions by leukocytes and enhances non-specific immune defense in an Atlantic salmon (Salmo salar) immunostimulation model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

65072-00-6

Solid

Off-white to light yellow

[Casein hydrolysate]

Room temperature in continental US; may vary elsewhere.

• [1]. Kitts DD, et al. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23.  [Content Brief]

  [2]. Phelan M, et al. Potential bioactive effects of casein hydrolysates on human cultured cells[J]. International Dairy Journal, 2009, 19(5): 279-285.

  [3]. Jiang Y, et al. Preparation of casein hydrolysate by two-step enzymatic hydrolysis and its immunomodulatory activities in vitro and in vivo[J]. Food Bioscience, 2024, 59: 104007.